Which describes you?


Product?

The link you selected will take you away from this site to one that is not owned or controlled by Genentech and Biogen Idec. Genentech and Biogen Idec are not part of the site. Nor does it control the content. Genentech does not guarantee the information on the page. Your use of third-party websites is at your own risk and is subject to the terms and conditions of use for such sites. 

The information contained in this section of the site is for U.S. health care professionals only. Please click "OK" if you are a U.S. health care professional.

Do you need to know more about what we offer for each of our products?

Do you want to know more about Rituxan Access Solutions? To see what we offer, click here.


About Us


Rituxan Access Solutions: connecting patients to the medicine they need.

We are committed to helping all patients access our medicines, regardless of their ability to pay. Our dedicated staff of Specialists can help:

  • Resolve benefits and coverage issues
  • Find co-pay assistance for underinsured patients
  • Provide free medicine for eligible uninsured patients through the Genentech® Access to Care Foundation (GATCF)
  • Individualize services to meet your patients' specific needs

Since 1985, when its first product was approved, Genentech has donated approximately $1.5 billion in free medicine to uninsured patients through GATCF and other product donation programs. In addition, Genentech has donated approximately $250 million to various independent, non-profit organizations for co-pay assistance since 2005.

Rituxan Access Solutions helps to resolve specific access and reimbursement issues for individual patients every day. Our dedicated Specialists help bring patient treatment and practice solutions together.

 

INDICATIONS

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Previously untreated CD20-positive CLL in combination with FC chemotherapy
  • Previously treated CD20-positive CLL in combination with FC chemotherapy

People with serious infections should not receive RITUXAN

IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).

RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.

The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. The most common side effects of RITUXAN in patients with chronic lymphocytic leukemia were infusion reactions and low white blood cells. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.

Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including the Medication Guide.

Rituxan® and its logo are trademarks of Biogen Idec, Inc.
The Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.

INDICATIONS

RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Previously untreated CD20-positive CLL in combination with FC chemotherapy
  • Previously treated CD20-positive CLL in combination with FC chemotherapy

People with serious infections should not receive RITUXAN

IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).

RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.

The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. The most common side effects of RITUXAN in patients with chronic lymphocytic leukemia were infusion reactions and low white blood cells. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.

Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including the Medication Guide.

Rituxan® and its logo are trademarks of Biogen Idec, Inc.
The Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.

Health Care Professional
Genentech Access Solutions can assist in managing the patients you refer to us. However, the use of our forms and the accuracy of the information provided are your responsibility and not that of Genentech Access Solutions.

Patient / Caregiver
Genentech Access Solutions can help you in getting the medicine you need. However, it is up to your doctor's office to provide accurate information when filling out our forms.

© 2010 Genentech USA, Inc. All rights reserved. This site is intended for U.S. residents only.